Загрузка...
Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
BACKGROUND: Regorafenib, a multitargeted tyrosine kinase inhibitor, proved to be active in patients with soft tissue sarcomas (STS). METHODS: We conducted an open-label, non-randomized, single-center phase II study in advanced pretreated STS patients. Patients received regorafenib 160 mg daily on da...
Сохранить в:
| Опубликовано в: : | Medicine (Baltimore) |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer Health
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7328961/ https://ncbi.nlm.nih.gov/pubmed/32590747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000020719 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|